UB Paderborn / Katalog / Suche / in CDI

1 – 14 von 14

Sortiert nach

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

Cancers, 2022-06, Vol.14 (12), p.2829

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort

Current oncology (Toronto), 2024-03, Vol.31 (3), p.1656-1666

2024

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.191-197

2023

Link zum Volltext

Verfügbarkeit prüfen

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Critical reviews in oncology/hematology, 2022-04, Vol.172, p.103639-103639, Article 103639

2022

Link zum Volltext

Verfügbarkeit prüfen

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9019-9019

2023

Link zum Volltext

Verfügbarkeit prüfen

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Journal of cancer research and clinical oncology, 2023-11, Vol.149 (16), p.15095-15102

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.342-342

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

Targeted oncology, 2023-07, Vol.18 (4), p.585-591

2023

Link zum Volltext

Verfügbarkeit prüfen

Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241236451-17588359241236451

2024

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2024-04, Vol.42 (12), p.1350-JCO2301521

2024

Link zum Volltext

Verfügbarkeit prüfen

Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Therapeutic advances in medical oncology, 2024-03, Vol.16

2024

Link zum Volltext

Verfügbarkeit prüfen

Kompetenzen und Komptenzmessung

Allgemeine schweizerische Militärzeitschrift, 2009-07, Vol.175 (7), p.24

2009

Link zum Volltext

Verfügbarkeit prüfen

Molecular parameters in melittin immunogenicity

Journal of peptide science, 1997-07, Vol.3 (4), p.267-276

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(14)

Sprache

Englisch
(13)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(9)
Science & Technology
(9)
Oncology
(8)
Humans
(7)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Lung Neoplasms - Drug Therapy
(4)
Immunotherapy
(3)
Life Sciences
(3)
Lung Cancer
(3)
Mutation
(3)
Non-Small Cell Lung Cancer
(3)
Retrospective Studies
(3)
Cancer
(2)
Chemotherapy
(2)
Hematology
(2)
Immune Checkpoint Inhibitors
(2)
Lung Neoplasms - Pathology
(2)
Male
(2)
Medicine
(2)
Medicine & Public Health
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer

Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

Resected EGFR -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR -Mutant Non-Small-Cell Lung Cancer

Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Kompetenzen und Komptenzmessung

Molecular parameters in melittin immunogenicity

Suchergebnisse filtern